Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus

Epratuzumab, a humanized anti-CD22 monoclonal antibody, is under investigation as a therapeutic antibody in non-Hodgkin's lymphoma and systemic lupus erythematosus (SLE), but its mechanism of action on B-cells remains elusive. Treatment of SLE patients with epratuzumab leads to a reduction of c...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Arthritis research & therapy 2010-01, Vol.12 (6), p.R204-R204, Article R204
Hauptverfasser:	Daridon, Capucine, Blassfeld, Daniela, Reiter, Karin, Mei, Henrik E, Giesecke, Claudia, Goldenberg, David M, Hansen, Arne, Hostmann, Arwed, Frölich, Daniela, Dörner, Thomas
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal, Humanized B cells B-Lymphocytes - cytology B-Lymphocytes - drug effects B-Lymphocytes - immunology B-Lymphocytes - metabolism Cell adhesion molecules Cell Adhesion Molecules - biosynthesis Cell Adhesion Molecules - drug effects Cell Adhesion Molecules - immunology Cell migration Cell Movement Cell Separation Chemotaxis, Leukocyte - drug effects Complications and side effects Dosage and administration Drug targeting Drug therapy Female Flow Cytometry Humans Integrin beta Chains - biosynthesis Integrin beta1 - biosynthesis L-Selectin - biosynthesis Lupus Erythematosus, Systemic - immunology Lupus Erythematosus, Systemic - metabolism Male Monoclonal antibodies Physiological aspects Sialic Acid Binding Ig-like Lectin 2 - metabolism Systemic lupus erythematosus
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!